晚期结肠癌的第三线治疗对长期生存有好处:一个病例报告
Ju Su1, Yuqing Kuang1, Yiwen Wu2
1Department of Oncology, People's Hospital of Xiangxi Autonomous Prefecture/The First Affiliated Hospital of Jishou University, Jishou, China.
Frontiers in immunology
|September 29, 2025
概括
第三线免疫疗法与向治疗相结合,可为转移性结直肠癌 (mCRC) 患者提供长期无进展的生存期. 这项案例研究突出了弗鲁昆丁尼布和辛蒂利马布作为对熟练不匹配修复 (pMMR) mCRC.的有希望的治疗方法.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 临床医学 临床医学
背景情况:
- 大肠直肠癌 (CRC) 的发病率和死亡率显著.
- 转移性CRC (mCRC) 的第三线治疗选择有限.
- 肝转移复杂化了CRC的管理.
研究的目的:
- 报告一个具有肝转移的晚期CRC病例.
- 评估第三线免疫疗法和向治疗的疗效.
- 为管理类似的mCRC病例提供临床参考.
主要方法:
- 一名69岁的男性被诊断出患有上升性结肠腺癌和肝转移 (pMMR).
- 接受了新辅助化疗,手术和辅助化疗.
- 第三线治疗包括fruquintinib (向治疗) 和sintilimab (免疫疗法).
主要成果:
- 在初始治疗后疾病的进展.
- 通过第三线fruquintinib和sintilimab获得超过38个月的无进展生存期.
- 在一个难以治疗的mCRC病例中证明了长时间的存活.
结论:
- 弗鲁昆丁尼布加上辛蒂利马布显示出作为pMMR mCRC的第三线选择的希望.
- 组合疗法可以克服晚期CRC的治疗阻力.
- 这种治疗策略需要进一步的研究.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648


